Copper-binding tripeptide complex

GHK-Cu

aka Glycyl-L-histidyl-L-lysine copper complex · Copper tripeptide-1 · Prezatide copper

Evidence grade
Grade C: Preliminary human data
for topical skin and hair cosmetic use (injectable 'systemic anti-ageing' has no human trials)
User score everyone · n = 64
US FDA Not approved checked 2026-11-13
WADA 2026 Not named no clearance either · checked 2026-11-13
EU EMA medicinal authorization not found; cosmetic ingredient naming/database presence is not drug approval or a blanket authorization. · checked 2026-11-13

Goals: Longevity · Skin & hair Compare with another peptide →

User reports

approximate — combined from two independent Reddit reads

Men 45–60

1 man aged 45–60

small sample · n = 1

Outcome negative 1 of 1 · positive 1 of 1

Benefits hair 1 of 1 · other 1 of 1 · skin 1 of 1

Side effects other 1 of 1

Why stopped side effects 1 of 1

Stopped 1 of 1 Used with other compounds 0 of 1

All men

3 men

small sample · n = 3

Outcome negative 1 of 3 · positive 1 of 3 · unclear 1 of 3

Benefits hair 1 of 3 · other 1 of 3 · skin 1 of 3

Side effects other 1 of 3

Why stopped side effects 1 of 3

Stopped 1 of 3 Used with other compounds 1 of 3

Everyone

64 people

  • Positive: 44 of 64 (69%)
  • Mixed: 5 of 64 (8%)
  • Negative: 4 of 64 (6%)
  • No effect: 4 of 64 (6%)
  • Unclear: 7 of 64 (11%)
Benefits reported of 64
Benefits reported (n = 64)
ItemReports
Skin33 of 64 (52%)
Hair31 of 64 (48%)
Other3 of 64 (5%)
Inflammation2 of 64 (3%)
Injury healing2 of 64 (3%)
Joints / tendons1 of 64 (2%)
Recovery1 of 64 (2%)
Side effects reported of 64
Side effects reported (n = 64)
ItemReports
Injection site7 of 64 (11%)
Other5 of 64 (8%)
Acne2 of 64 (3%)
Why people stopped of 64
Why people stopped (n = 64)
ItemReports
Side effects3 of 64 (5%)
No effect2 of 64 (3%)

Stopped 5 of 64 (8%) Used with other compounds 22 of 64 (34%)

User reports are anecdata, not evidence: self-selected, unverified, often combined with other compounds.

In their words

  • “I'm an older male.”

  • “I've definitely noticed some thickening of my hair and my skin is noticeably thicker and smoother”

  • “I'm very happy with the results so far.”

  • “I'm on my 7th week of GHK-Cu at 2mg to 3.5mg a day subq. I'm in my 50s, male, in reasonably good shape.”

  • “I've noticed the deep lines in my forehead have become flatter. My nails and hair have been growing faster.”

  • “I've been using GHK-cu at 2-3mg per day for 12 weeks now and honestly - my skin has never looked worse.”

  • “When I first started out with the copper, injection site irritation was epic. Almost quit.”

Read summaries and method notes

Read 1. One verified man aged 45–60: a 45M topical user who developed new fine facial lines after about ten days, stopped, and improved afterwards. A self-described "older male" (exact age unknown) reported thicker hair, thicker smoother skin and smaller under-eye bags after just over four weeks at 2.5 mg; a 58F injectable user reported eyebrow/eyelash growth and healing of hidradenitis-type cysts. Topical and injectable routes are not interchangeable evidence.

Read 2. One man aged 45–60: a man in his 50s, 7 weeks SubQ at 2–3.5 mg/day, reported flatter forehead lines, thicker skin, fading pigmentation and faster hair and nail growth, with no side effects. Everyone (n=63, 13 threads, many older users without stated sex) is strongly positive (43 positive, 5 mixed) for skin (32) and hair (30), with effects after 3–4 weeks for shedding and 6–16 weeks for visible change. Problems: injection pain/burning/bruising (7) and, in a minority, "copper uglies" (saggy, dry or blemished skin) that faded after stopping. 22 stacked (KLOW blends, finasteride, minoxidil).

Note 1. Topical and injectable use were both counted but kept distinct. The self-described older male's age was not inferred, so he is excluded from men_45_60. Several injection-pain comments lacked a complete outcome and were not counted.

Note 2. Only two self-reports stated male sex; several stated ages without sex (58, >50, 50, 61) or mentioned 'my wife', which does not count. Female/mixed skin and hair threads dominate. Two suspected vendor-shill comments were excluded; AHK-Cu-only reports were not counted.

Each read counted people independently. Overlap between the two reads is estimated from shared threads and removed; counts are approximate. How we count.

Summary

Naturally occurring copper-binding tripeptide found in human plasma. Small formulation-specific topical studies show mixed results; exact age-related concentration figures and a general claim of excellent systemic safety were not verified.

Proposed mechanism

  • Laboratory studies report effects on extracellular matrix and gene expression; these do not establish reversal of human aging.
  • Copper delivery may influence copper-dependent pathways; this does not prove that the intact complex is an enzyme cofactor in patients.
  • Antioxidant and organ-protection, neuroprotection and bone-healing claims are preclinical, not established human benefits.

Safety

  • Minor topical skin reactions occurred in a small wrinkle study.
  • Hyperpigmentation signal occurred with dermaroller plus a specific copper-peptide serum.
  • Injectable immunogenicity, aggregation and impurity risks remain unresolved.
  • Long-term systemic, pregnancy and lactation safety are not established.
  • The term copper uglies has no verified clinical incidence in retrieved evidence.

From labels, regulators and trials. No signal in small studies ≠ safe.

Evidence C topical skin and hair cosmetic use (injectable 'systemic anti-ageing' has no human trials)

C stands. Small, formulation-specific topical trials give mixed results: positives for wrinkles, eyebrows and diabetic ulcers; nulls after laser resurfacing and in venous ulcers; and a nonrandomized acne-scar comparison with no benefit and a pigmentation signal. None is a solid RCT, so not B; human data exist, so not D.

Human trials · 6

  1. PMID 14951501992RCT; evaluator-blinded; evaluable completers 86 people

    Venous stasis ulcers; topical tripeptide-copper complex, exact identity less explicit in abstract

    0.4% copper-tripeptide cream did not outperform vehicle. Source

  2. PMID 171476441994Multicenter RCT; evaluator-blinded; participant count not found in accessible abstract size not reported

    Diabetic neuropathic ulcers with intensive standardized wound care

    Greater plantar-ulcer area closure with specific copper-peptide gel; median 98.5% versus 60.8%; not complete-healing patient percentages. Source

  3. PMID 168471712006Randomized trial; blinded objective evaluators; completers 13 people

    Patients after CO2 laser skin resurfacing

    No objective erythema/wrinkle/skin-quality advantage; satisfaction favored topical copper peptide. Source

  4. DOI 10.4172/2329-8847.10001662016RCT; double-blind; split-face; 39 completed 40 people

    Women aged 40–65; facial wrinkles

    Nano-carrier serum improved measured wrinkles; control lacked both peptide and carrier, limiting attribution.

  5. Bo et al. 2026 proceedings2026RCT; double-blind; vehicle-controlled split-face 18 people

    Adults aged 18–40; sparse eyebrows

    Reported improved eyebrow count/diameter after 12 weeks; small proceedings report.

  6. DOI 10.25259/JCAS_56_20252026Nonrandomized comparative study; online 2025, issue 2026 40 people

    Acne scars; dermaroller with or without copper-tripeptide serum

    No significant later between-group advantage; hyperpigmentation in 8/20 combination patients versus 0/20 controls.

Bar length = trial size on a log scale.

Dose ranges

Reported ranges from labels and studies, with context. Not a recommendation.

  • clinical trial
    0.4% topical copper-tripeptide cream in venous-ulcer RCT Source
  • clinical trial
    2% topical GHK-Cu serum twice daily for 12 weeks in eyebrow study Source on a non-primary host — not linked
  • clinical trial
    1% topical copper-peptide serum after each of five dermaroller sessions in nonrandomized acne-scar study Source on a non-primary host — not linked

Editorial ratings EDITORIAL

Editors’ judgement, 0–5. Opinion, not data; separate from grade and user score.

  • Safety 5 out of 5
  • Sleep 3 out of 5
  • Recovery 4 out of 5
  • Cognitive 3.5 out of 5

Sources

  1. pubmed.ncbi.nlm.nih.gov/1495150/
  2. pubmed.ncbi.nlm.nih.gov/17147644/
  3. pubmed.ncbi.nlm.nih.gov/16847171/
  4. fda.gov/media/94155/download
  5. wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
  6. fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-pres
  7. hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
  8. govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.htm
  9. fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-c
  10. ema.europa.eu/en/medicines
  11. pmc.ncbi.nlm.nih.gov/articles/PMC13610439

Reddit threads read · 15

8 further sources on commercial or non-primary hosts not listed.

Research checked 2026-11-13.